* SpringWorks Therapeutics Inc SWTX.OQ SWTX.O is
expected
to show a rise in quarterly revenue when it reports results on
August 7 for the period ending June 30 2024
* The Stamford Connecticut-based company is expected to
report
revenue of $34.343 million, according to the mean estimate from
7 analysts, based on LSEG data.
* LSEG's mean analyst estimate for SpringWorks Therapeutics
Inc
is for a loss of $1.11 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for SpringWorks
Therapeutics Inc is $63.13, above its last closing price
of $33.43.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -1.16 -1.17 -1.18 Missed -0.7
Dec. 31 2024 -1.24 -1.24 -1.45 Missed -16.9
Sep. 30 2023 -1.29 -1.33 -1.27 Beat 4.5
Jan. 1 0001 -1.25 -1.26 -1.25 Beat 1
Mar. -1.31 -1.24 -1.18 Beat 5
31 2023
Dec. 31 2022 -1.22 -1.22 -1.17 Beat 4.2
Sep. 30 2022 -1.30 -1.32 -1.37 Missed -3.8
Jun. 30 2022 -1.22 -1.20 -1.41 Missed -17.2
This summary was machine generated August 5 at 15:24 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)